Immunotherapy for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: a real-world analysis

BACKGROUND: Due to less sensitivity to classic tyrosine kinase inhibitors, effective first-line treatment is limited in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) or human epidermal growth factor receptor 2 (HER2) exon 20 insertion (ex20ins) mutations. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Mai, Huang, Qian, Yu, Min, Xue, Jianxin, Huang, Meijuan, Lu, You, Zhang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183400/
https://www.ncbi.nlm.nih.gov/pubmed/37197626
http://dx.doi.org/10.21037/tlcr-23-167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183400/
https://www.ncbi.nlm.nih.gov/pubmed/37197626
http://dx.doi.org/10.21037/tlcr-23-167

Ejemplares similares